215 related articles for article (PubMed ID: 30102628)
1. How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril.
Augustin M; Schoretsanitis G; Gründer G; Haen E; Paulzen M
J Clin Psychopharmacol; 2018 Oct; 38(5):498-501. PubMed ID: 30102628
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Paulzen M; Haen E; Hiemke C; Fay B; Unholzer S; Gründer G; Schoretsanitis G
J Affect Disord; 2018 Feb; 227():506-511. PubMed ID: 29156365
[TBL] [Abstract][Full Text] [Related]
3. Reduced clearance of venlafaxine in a combined treatment with quetiapine.
Paulzen M; Schoretsanitis G; Hiemke C; Gründer G; Haen E; Augustin M
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul; 85():116-121. PubMed ID: 29702137
[TBL] [Abstract][Full Text] [Related]
4. Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.
Hefner G; Unterecker S; Shams ME; Wolf M; Falter T; Haen E; Hiemke C
J Neural Transm (Vienna); 2015 Nov; 122(11):1609-17. PubMed ID: 25940834
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database.
Schoretsanitis G; Haen E; Gründer G; Hiemke C; Endres K; Ridders F; Correll CU; Paulzen M
Eur J Clin Pharmacol; 2019 Aug; 75(8):1109-1116. PubMed ID: 30968172
[TBL] [Abstract][Full Text] [Related]
6. Sex and body weight are major determinants of venlafaxine pharmacokinetics.
Schoretsanitis G; Haen E; Hiemke C; Fay B; Unholzer S; Correll CU; Gründer G; Paulzen M
Int Clin Psychopharmacol; 2018 Nov; 33(6):322-329. PubMed ID: 30028351
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic correlates of venlafaxine: associated adverse reactions.
Schoretsanitis G; Haen E; Hiemke C; Endres K; Ridders F; Veselinovic T; Gründer G; Paulzen M
Eur Arch Psychiatry Clin Neurosci; 2019 Oct; 269(7):851-857. PubMed ID: 30923938
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
9. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
10. Influence of Zuojin Pill on the Metabolism of Venlafaxine in Vitro and in Rats and Associated Herb-Drug Interaction.
Li Y; Li J; Yan D; Wang Q; Jin J; Tan B; Qiu F
Drug Metab Dispos; 2020 Oct; 48(10):1044-1052. PubMed ID: 32561594
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine.
Kowalewski C; Haen E; Hiemke C; Ridders F; Endres K; Gründer G; Paulzen M; Schoretsanitis G
Int Clin Psychopharmacol; 2019 Sep; 34(5):241-246. PubMed ID: 31094902
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.
Kuzin M; Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
Clin Pharmacokinet; 2018 Jun; 57(6):729-737. PubMed ID: 28866861
[TBL] [Abstract][Full Text] [Related]
13. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions.
Unterecker S; Hiemke C; Greiner C; Haen E; Jabs B; Deckert J; Pfuhlmann B
Pharmacopsychiatry; 2012 Sep; 45(6):229-35. PubMed ID: 22426847
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
Paulzen M; Haen E; Gründer G; Lammertz SE; Stegmann B; Schruers KR; Walther S; Schoretsanitis G
J Psychopharmacol; 2016 Aug; 30(8):803-9. PubMed ID: 27251417
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
Teng R; Kujacic M; Hsia J
Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
[TBL] [Abstract][Full Text] [Related]
16. [Medication adherence with the fixed combination of ramipril and amlodipine].
Simonyi G; Ferenci T
Orv Hetil; 2014 Nov; 155(47):1882-8. PubMed ID: 25403283
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.
Men X; Taylor ZL; Marshe VS; Blumberger DM; Karp JF; Kennedy JL; Lenze EJ; Reynolds CF; Stefan C; Mulsant BH; Ramsey LB; Müller DJ
Clin Pharmacol Ther; 2024 May; 115(5):1065-1074. PubMed ID: 38284409
[TBL] [Abstract][Full Text] [Related]
18. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 May; 47(5):481-504. PubMed ID: 38664354
[TBL] [Abstract][Full Text] [Related]
19. Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose-corrected concentrations of venlafaxine and O-desmethylvenlafaxine: A retrospective analysis of therapeutic drug monitoring data in a Chinese population.
Wang ZZ; Deng SH; Lu HY; Li L; Zhu XQ; Hu JQ; Xie HS; Chen HZ; Chen YQ; Zhang M; Fang ZY; Wen YG; Shang DW
Hum Psychopharmacol; 2020 May; 35(3):e2733. PubMed ID: 32239743
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.
Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
